Dr. Jessica Gordon receives the Clinician Career Development Award
We are proud to inform you that Dr. Jessica Gordon has been selected as one of the recipients of the Clinician Career Development Award. This award is given to scientists who have been identified as future leaders of research in their respected fields. The awardees have demonstrated well-defined research activities integrated with clinical responsibilities in their respected fields.
Rheum to Grow: Stories of Health and Humanity at Hospital for Special Surgery (Calling for Submissions)
This is a journal for, by and about our patients and their caregivers. We welcome poetry, photography or prose, on or related to themes of health, healing, navigating illness, mind, body and/or self-transformations within the field of rheumatology. We will accept pieces from patients with arthritis, autoimmune diseases, pain disorders affecting joints, and osteoporosis. Relevant book reviews, commentaries and opinion pieces, and contributions on or related to ethics, public health/health policy or careers in rheumatology are all welcome. We are eager for pieces from patients who have something to say about medicine, rheumatology in particular, and health professionals, practicing or retired. Learn more about how to submit.
Hospital for Special Surgery's Scleroderma, Vasculitis, & Myositis Center has received a challenge grant from an anonymous donor to match every dollar donated to the Center's Rudolph Rupert Scleroderma Research Program, up to $50,000. Your support will fund critical scleroderma research, as well as community outreach and patient and physician education. Learn more about how to leverage your gift and help fight scleroderma.
The FDA has recently approved Rituxan, in combination with glucocorticoids, for patients with Wegener’s granulomatosis (WG) and microscopic polyangiitis (MPA), which are both rare autoimmune diseases that largely affects small blood vessels of the kidneys, lungs, sinuses, and a variety of other organs.
The approval is based on the results of the NIH sponsored RAVE (Rituxan in ANCA-Associated Vasculitis) trial. HSS was a participating site for the trial under the leadership of our very own, Dr. Robert Spiera. Dr. Spiera was also the third author on “Rituximab versus cyclophosphamide for ANCA-associated vasculitis,” the New England Journal of Medicine publication which presented the results of the trial.
Congratulations to Dr. Robert Spiera, Dr. Jessica Gordon and their team of investigators on the recent publication of their clinical trial of imatinib in the treatment of patients with scleroderma in Annals of Rheumatic Diseases (March, 2011). Their paper entitled, “Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial” is available in abstract form, as full text HTML, and is also downloadable as a PDF. This is indeed an accomplishment for our institution and a reflection of the ongoing efforts that are being made to advance research and therapeutics in the area of scleroderma.